Catalyst Pharmaceutical CPRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $588.99M+19.8% | $491.73M+23.5% | $398.2M+85.9% | $214.2M+52.1% | ||
| $87.25M+26.7% | $68.85M+32.5% | $51.97M+51.1% | $34.39M+57.2% | ||
| $501.74M+18.6% | $422.89M+22.1% | $346.24M+92.6% | $179.81M+51.2% | ||
| 85.2%-0.8pp | 86%-1.0pp | 86.9%+3.0pp | 83.9%-0.5pp | ||
| $12.71M+0.5% | $12.65M-86.4% | $93.15M+371% | $19.79M+16.8% | ||
| $193.75M+9.0% | $177.74M+32.9% | $133.71M+134% | $57.09M+15.0% | ||
| $257.78M+32.1% | $195.12M+125% | $86.81M-14.8% | $101.84M+94.4% | ||
| 43.8%+4.1pp | 39.7%+17.9pp | 21.8%-25.7pp | 47.5%+10.3pp | ||
| $25.74M+21.8% | $21.14M+175% | $7.7M+167% | $2.88M+922% | ||
| $283.52M+31.1% | $216.26M+129% | $94.51M-9.7% | $104.72M+98.8% | ||
| $69.19M+32.1% | $52.37M+127% | $23.1M+6.8% | $21.64M+64.1% | ||
| $214.33M+30.8% | $163.89M+130% | $71.41M-14.0% | $83.08M+110% | ||
| 36.4%+3.1pp | 33.3%+15.4pp | 17.9%-20.9pp | 38.8%+10.8pp | ||
| $1.69+29.0% | $1.31+115% | $0.61-18.7% | $0.75+103% | ||
| $1.76+27.5% | $1.38+103% | $0.68-15.0% | $0.80+111% | ||
| 508.8M+2.1% | 498.4M+11.3% | 448M+1.4% | 441.7M+2.7% | ||
| 488.5M+3.4% | 472.4M+11.2% | 424.7M+3.0% | 412.3M-0.4% | ||
| $37.5M+0.3% | $37.38M+14.8% | $32.57M+2,866% | $1.1M— | ||
| $214.26M+30.7% | $163.94M+130% | $71.4M-14.2% | $83.25M+112% | ||
| $331.21M+11.7% | $296.61M-4.7% | $311.39M+177% | $112.37M+27.0% | ||
| -$64K-228% | $50K+600% | -$10K-106% | $180K+201% | ||
| $25.74M+21.8% | $21.14M+175% | $7.7M+167% | $2.88M+922% | ||
| $588.99M+19.8% | $491.73M+23.5% | $398.2M+85.9% | $214.2M+52.1% | ||
| $257.78M+32.1% | $195.12M+125% | $86.81M-14.8% | $101.84M+94.4% | ||
| $295.65M+26.9% | $232.9M+94.6% | $119.69M+16.7% | $102.56M+95.1% | ||
| $295.65M+26.9% | $232.9M+94.6% | $119.69M+16.7% | $102.56M+95.1% | ||
| 50.2%+2.8pp | 47.4%+17.3pp | 30.1%-17.8pp | 47.9%+10.5pp | ||
| $257.78M+32.1% | $195.12M+125% | $86.81M-14.8% | $101.84M+94.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Catalyst Pharmaceutical's profit margins?
- Gross margin is 86.0% and operating margin is 44.8%, with a 37.1% net margin.
- Where does Catalyst Pharmaceutical's income statement data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.